These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20885926)

  • 41. Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
    Mattila JP; Mirandola L; Chiriva-Internati M
    J Biomed Mater Res B Appl Biomater; 2019 Jan; 107(1):29-36. PubMed ID: 29504239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond.
    Chiriva-Internati M
    Int Rev Immunol; 2011; 30(2-3):138-49. PubMed ID: 21557640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.
    Wadle A; Mischo A; Strahl S; Nishikawa H; Held G; Neumann F; Wullner B; Fischer E; Kleber S; Karbach J; Jager E; Shiku H; Odunsi K; Shrikant PA; Knuth A; Cerundolo V; Renner C
    Yeast; 2010 Nov; 27(11):919-31. PubMed ID: 20672253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limited SP17 expression within tumors diminishes its therapeutic potential.
    Gjerstorff MF; Ditzel HJ
    Tissue Antigens; 2012 Dec; 80(6):523-7. PubMed ID: 23137323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
    Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
    Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
    Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
    Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
    Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
    Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
    Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.
    Liu Z; Poiret T; Persson O; Meng Q; Rane L; Bartek J; Karbach J; Altmannsberger HM; Illies C; Luo X; Harvey-Peredo I; Jäger E; Dodoo E; Maeurer M
    Cancer Immunol Immunother; 2018 Feb; 67(2):237-246. PubMed ID: 29058035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.
    Woloszynska-Read A; Mhawech-Fauceglia P; Yu J; Odunsi K; Karpf AR
    Clin Cancer Res; 2008 Jun; 14(11):3283-90. PubMed ID: 18519754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines.
    Chiriva-Internati M; Cobos E; Da Silva DM; Kast WM
    Cancer Immun; 2008 Apr; 8():8. PubMed ID: 18433090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
    Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L
    Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Universal tumor antigens as targets for immunotherapy.
    Gordan JD; Vonderheide RH
    Cytotherapy; 2002; 4(4):317-27. PubMed ID: 12396831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Muzikansky A; Kalil J; Festa-Neto C; Duncan LM
    J Immunol Res; 2015; 2015():761378. PubMed ID: 25954764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
    Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
    Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray.
    Toth L; Nagy B; Mehes G; Laszlo E; Molnar PP; Poka R; Hernadi Z
    Pathol Res Pract; 2018 Jul; 214(7):978-985. PubMed ID: 29801775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis.
    Cohen C; Lohmann CM; Cotsonis G; Lawson D; Santoianni R
    Mod Pathol; 2003 Jun; 16(6):574-83. PubMed ID: 12808063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.